Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 20;47(10):595-609.
doi: 10.1016/j.jgg.2020.11.001. Epub 2020 Nov 28.

Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms

Affiliations
Review

Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms

Sirvan Khalighi et al. J Genet Genomics. .

Abstract

Genome-scale studies focusing on molecular profiling of cancers across tissue types have revealed a plethora of aberrations across the genomic, transcriptomic, and epigenomic scales. The significant molecular heterogeneity across individual tumors even within the same tissue context complicates decoding the key etiologic mechanisms of this disease. Furthermore, it is increasingly likely that biologic mechanisms underlying the pathobiology of cancer involve multiple molecular entities interacting across functional scales. This has motivated the development of computational approaches that integrate molecular measurements with prior biological knowledge in increasingly intricate ways to enable the discovery of driver genomic aberrations across cancers. Here, we review diverse methodological approaches that have powered significant advances in our understanding of the genomic underpinnings of cancer at the cohort and at the individual tumor scales. We outline the key advances and challenges in the computational discovery of cancer mechanisms while motivating the development of systems biology approaches to comprehensively decode the biologic drivers of this complex disease.

Keywords: Functional impact; Multiomics integration; Mutational significance; Mutations; Pan-cancer analysis; Systems biology.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The other authors have no potential conflicts of interest to disclose.

Figures

Fig. 1.
Fig. 1.
Computational approaches to prioritize cancer driver genes and pathways categorized into major methodological categories: Analysis of Mutation Rate; Analysis of Protein Sequence, Structure and Function; Integrative Analysis of Multi-Omics Measurements; and Analysis of Whole Genomes. Also shown are the key computational tools within each category.
Fig. 2.
Fig. 2.
Schematic representation of the mutation rate-based approaches. BMR is estimated per gene (Gi) across all sequenced bases in the cohort of samples, and scores (Ni) represent the number of samples harboring mutations in Gi. In Gene Level mutation rate methods compare Ni with a significance threshold derived from the background mutation rate (BMR). If Ni ≫ BMR, Gi is identified as a significantly mutated gene (SMG); In contrast, Subnetwork Level methods evaluate BMR and Ni within a PPI network, where red and blue colors in the piecharts within each gene’s node indicate the proportion of mutated vs. wild-type samples. These methods then propagate the mutational frequencies throughout the network, using insights from heat diffusion processes, thus determining connected sub-networks that are more frequently targeted for mutations than expected.
Fig. 3.
Fig. 3.
Shown are the three major categories of methods that utilize either protein sequence homology, protein structure, and functional hotspots. A: Sequence homology-based methods are based on the insight that mutations in conserved regions (green box) are more likely to be deleterious as compared to the mutations in the non-conserved regions (red box). B: Protein structure- based methods not only utilize sequence homology but also model changes in the structure of the wild-type (WT) and mutated (MUT) protein. C: Since functional hotspots play an important role in protein-protein/protein-ligand interactions, this figure shows a close up view of the ligand binding pocket and how a mutation impacts the interaction of the protein with the ligand. The figure shows overlapping structures of the wildtype (blue) and mutated (red) proteins in addition to depicting the disrupted ligand interaction.
Fig. 4.
Fig. 4.
Schematic representation of the Multi-Omics integrative strategies. These methods integrate Multi-omics Data such as expression changes (RNA sequencing), copy number alterations (CNA), Mutation information (SNV) and epigenetic alterations (DNA Methylation) with Prior Biological Information such as PPI networks to estimate functional impacts of mutated genes on their downstream target genes. The Functional Impact of Mutated Genes, for example gene Gi, is evaluated by assessing for differential expression of downstream target genes {Gt1,Gt2….,Gtn} in mutated vs wild-type samples of Gi. These integrative analyses result in subnetworks containing mutated genes with significant impact on downstream targets. Note that the red and blue colors in the pie-charts within each mutated gene’s node indicate the proportion of mutated vs. wild-type samples; the shade of red indicates impact level of mutated gene Gi to the Gti.

Similar articles

Cited by

References

    1. Adli M, 2018. The CRISPR tool kit for genome editing and beyond. Nat. Commun 9, 1911. - PMC - PubMed
    1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR, 2010. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249. - PMC - PubMed
    1. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe’Er D, 2010. An integrated approach to uncover drivers of cancer. Cell 143, 1005–1017. - PMC - PubMed
    1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jager N, Jones DTW, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, Valdes-Mas R, van Buuren MM, van ‘t Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR, Genome APC, Consortium IBC, Consortium IM-S, PedBrain I, 2013. Signatures of mutational processes in human cancer. Nature 500, 415–421. - PMC - PubMed
    1. Alkan C, Coe BP, Eichler EE, 2011. Genome structural variation discovery and genotyping. Nat. Rev. Genet 12, 363–375. - PMC - PubMed

Publication types